| __timestamp | Vericel Corporation | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13774000 | 1499100000 |
| Thursday, January 1, 2015 | 22479000 | 1923500000 |
| Friday, January 1, 2016 | 27388000 | 2351400000 |
| Sunday, January 1, 2017 | 35610000 | 2564000000 |
| Monday, January 1, 2018 | 49007000 | 2397300000 |
| Tuesday, January 1, 2019 | 61139000 | 2503400000 |
| Wednesday, January 1, 2020 | 68836000 | 3344600000 |
| Friday, January 1, 2021 | 97592000 | 4529200000 |
| Saturday, January 1, 2022 | 106903000 | 4179100000 |
| Sunday, January 1, 2023 | 120998000 | 4650100000 |
Data in motion
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Vericel Corporation from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced Vericel Corporation in SG&A expenses, with a staggering 3,000% higher average annually. Notably, Viatris Inc.'s expenses peaked in 2023, reaching nearly 4.65 billion, while Vericel Corporation's expenses grew steadily, culminating in a 780% increase over the decade. This trend highlights Viatris Inc.'s expansive operational scale compared to Vericel Corporation's more measured growth. As these companies navigate the complexities of the healthcare market, their SG&A strategies offer valuable insights into their business models and market positioning.
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation